How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

876 results for

Actinic Keratoses

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Ingenol Mebutate Topical Gel A Status Report On Clinical Use Beyond Actinic Keratosis Full Text available with Trip Pro

Ingenol Mebutate Topical Gel A Status Report On Clinical Use Beyond Actinic Keratosis Ingenol mebutate is available as a topical gel formulation approved for the treatment of actinic keratosis. Two different concentrations are available for treatment of actinic keratoses at specific anatomic sites with the advantages of short durations of therapy and limited "down time" related to visible inflammation as compared to other topical agents. Due to the various modes of action of ingenol mebutate (...) , it has also been used for treatment of disease states other than actinic keratosis. This manuscript discusses the suggested modes of action of ingenol mebutate and reviews publications on the use of ingenol mebutate gel for cutaneous disorders other than actinic keratosis, including squamous cell carcinoma in-situ, basal cell carcinoma, actinic cheilitis, anogenital warts, and others. Author commentaries are also included with the goal of providing relevant clinical insights.

2016 The Journal of clinical and aesthetic dermatology

182. Defining Field Cancerization of the Skin Using Noninvasive Optical Coherence Tomography Imaging to Detect and Monitor Actinic Keratosis in Ingenol Mebutate 0.015%- Treated Patients Full Text available with Trip Pro

Defining Field Cancerization of the Skin Using Noninvasive Optical Coherence Tomography Imaging to Detect and Monitor Actinic Keratosis in Ingenol Mebutate 0.015%- Treated Patients The objective of this study was to assess the ability of optical coherence tomography to detect clinical and subclinical actinic keratoses confirmed by histopathology. The efficacy of ingenol mebutate treatment of actinic keratosis was also evaluated using optical coherence tomography, and correlation of treatment (...) actinic keratoses and the perilesional skin; three additional, suspected actinic keratoses lesions and perilesional areas were left untreated. Clinical and optical coherence tomography images were obtained for all lesions. Severity of local skin reactions was recorded to evaluate the relationship between local skin reaction and treatment effect.Optical coherence tomography analysis had a 100-percent (28/28) correlation with the clinical diagnosis of actinic keratosis and detected 16 of 22 (73

2016 The Journal of clinical and aesthetic dermatology

183. Tolerability of Ingenol Mebutate Gel, 0.05%, for Treating Patients with Actinic Keratosis on the Scalp in a Community Dermatology Practice Full Text available with Trip Pro

-identifying information on patients' medical history, pertinent history of actinic keratosis and skin cancer, and prior actinic keratosis treatments. Also collected was information on patients' treatment of scalp actinic keratosis with ingenol mebutate gel, 0.05%, including the occurrence of local skin reactions and their treatment, adverse events, and efficacy results at short-term and additional follow-up.In these patients, a significant proportion of the scalp had numerous actinic keratoses that were (...) often recurrent and/or hyperkeratotic. Most patients (83%) received cryosurgery to visible scalp actinic keratoses two weeks before ingenol mebutate treatment. Local skin reactions developed on the first day of topical treatment, were predominantly mild or moderate in intensity, and generally were resolved by 10 to 14 days. Local skin reactions were treated with a topical moisturizing product in 44 percent of the patients. Nearly half (45%) of the patients experienced application-site reactions

2016 The Journal of clinical and aesthetic dermatology

184. Current perspective on actinic keratosis: a review. (Abstract)

Current perspective on actinic keratosis: a review. Actinic keratoses (AKs) are common, with prevalence in the U.S.A. estimated at almost 40 million in 2004 and annual costs of > $1 billion (U.S.D.). However, there is no universally accepted definition of AK and thus it is difficult to identify reliably. AKs are lesions of epidermal keratinocytic dysplasia that result from chronic sun exposure and have the ability to progress to invasive squamous cell carcinoma (SCC), but clinicians disagree

2016 British Journal of Dermatology

185. Comparison of topical 5-fluorouracil formulations in actinic keratosis treatment Full Text available with Trip Pro

Comparison of topical 5-fluorouracil formulations in actinic keratosis treatment Comparison of topical 5-fluorouracil formulations in actinic keratosis treatment Comparison of topical 5-fluorouracil formulations in actinic keratosis treatment Kaur RR, Alikhan A, Maibach HI CRD summary The authors concluded that there was inadequate information to formulate a decision on the comparative efficacy of 0.5% and 5% 5-fluorouracil in patients with multiple actinic keratoses of the face and scalp (...) . The synthesis suffered from significant limitations that provided a substantial threat to the overall reliability of the review. Authors' objectives To evaluate the efficacy of 0.5% and 5% 5-fluorouracil cream monotherapy to treat patients with multiple actinic keratoses of the face and scalp. Searching PubMed and EMBASE were searched from 1965 to April 2009 for articles in English. Some search terms were reported. Study selection Randomised controlled trials (RCTS) that assessed 0.5% 5-fluorouracil once

2010 DARE.

186. Efficacy of PDT versus other interventions in randomized trials for the treatment of actinic keratoses a systematic review

Efficacy of PDT versus other interventions in randomized trials for the treatment of actinic keratoses a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2013 PROSPERO

187. Polypodium Leucotomos Supplementation in the Treatment of Scalp Actinic Keratosis: Could It Improve the Efficacy of Photodynamic Therapy? (Abstract)

Polypodium Leucotomos Supplementation in the Treatment of Scalp Actinic Keratosis: Could It Improve the Efficacy of Photodynamic Therapy? Actinic keratoses (AKs) are a common premalignant skin condition. Many treatments are available for AKs. Photodynamic therapy (PDT) is one of the most effective treatments. However, major concerns exist on the possibility of PDT-induced DNA-mutagenesis/immunosuppression, leading to AKs recurrence/treatment failure. An extract (PLE) from the fern polypodium

2015 Dermatologic Surgery Controlled trial quality: uncertain

188. Ingenol Mebutate (Picato®) With Methyl Aminolevulinate Photodynamic Therapy for the Treatment of Actinic Keratosis

PDT on day 5 Other Name: Picato® 0.015% and MAL PDT Drug: Ingenol mebutate Picato® day 2, 3, 4 Full treatment course with Ingenol mebutate (Picato®) 0.015% topical gel, apply day 2,3 and 4 Other Name: Picato® 0.015% Procedure: MAL PDT day 5 Methyl aminolevulate combined with Photodynamic therapy at day 5 Other Name: MAL PDT Outcome Measures Go to Primary Outcome Measures : Complete clearance of lesions [ Time Frame: 60 days ] The proportion of patients with complete clearance of actinic keratoses (...) Ingenol Mebutate (Picato®) With Methyl Aminolevulinate Photodynamic Therapy for the Treatment of Actinic Keratosis Ingenol Mebutate (Picato®) With Methyl Aminolevulinate Photodynamic Therapy for the Treatment of Actinic Keratosis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2015 Clinical Trials

189. Practical approach to the use of daylight photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: a European consensus. (Abstract)

Practical approach to the use of daylight photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: a European consensus. Daylight-mediated photodynamic therapy has been shown to be an effective therapy for actinic keratoses (AKs) and a simple and tolerable treatment procedure in three randomized Scandinavian studies and two recent Phase III randomized controlled studies in Australia and Europe.To establish consensus recommendations for the use of daylight photodynamic

2015 Journal of the European Academy of Dermatology and Venereology

190. A randomised, phase IIa exploratory trial to assess the safety and preliminary efficacy of LEO 43204 in patients with actinic keratosis. Full Text available with Trip Pro

A randomised, phase IIa exploratory trial to assess the safety and preliminary efficacy of LEO 43204 in patients with actinic keratosis. LEO 43204 is a novel ingenol derivative in development for the treatment of actinic keratosis.To compare the safety and preliminary efficacy of three doses of LEO 43204 with ingenol mebutate in actinic keratoses (AKs).Patients with at least three visible, discrete, nonkeratotic AKs on four separate selected treatment areas on the forearms received LEO 43204

2015 The British journal of dermatology Controlled trial quality: uncertain

191. Efficacy and safety of follow-up field treatment of actinic keratosis with ingenol mebutate 0.015% gel: a randomised controlled 12-month study. (Abstract)

Efficacy and safety of follow-up field treatment of actinic keratosis with ingenol mebutate 0.015% gel: a randomised controlled 12-month study. Ingenol mebutate (IngMeb) is a novel patient-applied topical field therapy for actinic keratosis.To demonstrate the efficacy and safety of follow-up IngMeb field treatment of actinic keratoses (AKs) present at 8 weeks after initial treatment or emerging in a previously cleared field.In this phase III, randomized, double-blind study in patients with 4-8

2015 The British journal of dermatology Controlled trial quality: uncertain

192. A randomized trial comparing simultaneous vs. sequential field treatment of actinic keratosis with ingenol mebutate on two separate areas of the head and body. Full Text available with Trip Pro

A randomized trial comparing simultaneous vs. sequential field treatment of actinic keratosis with ingenol mebutate on two separate areas of the head and body. Actinic keratoses (AKs) are precursors to invasive squamous cell carcinoma and can progress if untreated. Limited data support the use of ingenol mebutate to treat AKs on more than one area of the body simultaneously.To investigate safety, efficacy and treatment satisfaction when treating separate areas simultaneously or sequentially

2015 Journal of the European Academy of Dermatology and Venereology Controlled trial quality: uncertain

193. Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis

: November 30, 2015 Last Update Posted : June 15, 2017 Sponsor: Actavis Inc. Information provided by (Responsible Party): Actavis Inc. Study Details Study Description Go to Brief Summary: This study is to evaluate the efficacy and safety of a generic formulation of fluorouracil 0.5% cream against the brand product (Carac) in subjects with actinic keratoses Condition or disease Intervention/treatment Phase Actinic Keratosis Drug: Carac Cream Drug: Generic Fluorouracil Cream Drug: Placebo Phase 3 Detailed (...) Description: This is a multicenter, double-blind, vehicle-controlled, parallel group comparison study of a generic fluorouracil cream, 0.5% and Carac (fluorouracil) cream, 0.5% in subjects with actinic keratoses on the full face or balding scalp. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 410 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Investigator, Outcomes Assessor

2015 Clinical Trials

194. Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial. Full Text available with Trip Pro

Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial. Topical fluorouracil was demonstrated to be effective in reducing the number of actinic keratoses (AKs) for up to 6 months, but no randomized trials studied its long-term efficacy.To evaluate the long-term efficacy of a single course of fluorouracil cream, 5%, for AK treatment.The Veterans Affairs Keratinocyte Carcinoma Chemoprevention (VAKCC) trial was a randomized, double-blinded (...) study reports on AK counts and treatments, which were secondary outcomes of the VAKCC trial. Actinic keratoses on the face and ears were counted by study dermatologists at enrollment and at study visits every 6 months. The number of spot treatments for AKs on the face and ears at semiannual study visits and in between study visits was recorded.The number of AKs on the face and ears per participant was not different between the fluorouracil and control groups at randomization (11.1 vs 10.6, P > .10

2015 JAMA dermatology Controlled trial quality: predicted high

195. A prospective randomized exploratory study comparing the efficacy of once-daily topical 0.5% 5-fluorouracil in combination with 10.0% salicylic acid (5-FU/SA) vs. cryosurgery for the treatment of hyperkeratotic actinic keratosis. (Abstract)

A prospective randomized exploratory study comparing the efficacy of once-daily topical 0.5% 5-fluorouracil in combination with 10.0% salicylic acid (5-FU/SA) vs. cryosurgery for the treatment of hyperkeratotic actinic keratosis. Actinic keratoses (AKs) are clinically significant and require therapy. Efficacy of low-dose (0.5%) 5-fluorouracil with 10% salicylic acid (5-FU/SA) has been shown in randomized comparative trials of hyperkeratotic lesions of various grades.To evaluate the efficacy

2015 Journal of the European Academy of Dermatology and Venereology : JEADV Controlled trial quality: uncertain

196. Ingenol mebutate gel for actinic keratosis. Full Text available with Trip Pro

Ingenol mebutate gel for actinic keratosis. Actinic keratosis is a common precursor to sun-related squamous-cell carcinoma. Treating actinic keratoses and the surrounding skin area (i.e., field therapy) can eradicate clinical and subclinical actinic keratoses. Topical field therapy currently requires weeks or months of treatment. We investigated the efficacy and safety of a new topical field therapy for actinic keratosis, ingenol mebutate gel (0.015% for face and scalp and 0.05% for trunk (...) and extremities).In four multicenter, randomized, double-blind studies, we randomly assigned patients with actinic keratoses on the face or scalp or on the trunk or extremities to receive ingenol mebutate or placebo (vehicle), self-applied to a 25-cm(2) contiguous field once daily for 3 consecutive days for lesions on the face or scalp or for 2 consecutive days for the trunk or extremities. Complete clearance (primary outcome) was assessed at 57 days, and local reactions were quantitatively measured.In

2012 NEJM Controlled trial quality: predicted high

197. Arsenical Keratoses Associated with Carcinoma of the Internal Organs Full Text available with Trip Pro

Arsenical Keratoses Associated with Carcinoma of the Internal Organs 13511317 2000 07 01 2018 12 01 0008-4409 78 6 1958 Mar 15 Canadian Medical Association journal Can Med Assoc J Arsenical keratoses associated with carcinomas of the internal organs. 416-9 ROSSET M M eng Journal Article Canada Can Med Assoc J 0414110 0008-4409 0 Arsenicals N712M78A8G Arsenic OM Arsenic Arsenic Poisoning Arsenicals Humans Keratosis etiology Keratosis, Actinic Neoplasms complications 5834:3662:58:320:401 ARSENIC

1958 Canadian Medical Association Journal

198. Key differences identified between actinic keratosis and cutaneous squamous cell carcinoma by transcriptome profiling. Full Text available with Trip Pro

Key differences identified between actinic keratosis and cutaneous squamous cell carcinoma by transcriptome profiling. Cutaneous squamous cell carcinoma (cSCC) is one of the most common malignancies in fair-skinned populations worldwide and its incidence is increasing. Despite previous observations of multiple genetic abnormalities in cSCC, the oncogenic process remains elusive. The purpose of this study was to elucidate key molecular events associated with progression from premalignant actinic (...) keratoses (AKs) to invasive cSCC by transcriptome profiling.We combined laser capture microdissection with the Affymetrix HGU133 Plus 2.0 microarrays to profile 30 cSCC and 10 AKs.We identified a core set of 196 genes that are differentially expressed between AK and cSCC, and are enriched for processes including epidermal differentiation, cell migration, cell-cycle regulation and metabolism. Gene set enrichment analysis highlighted a key role for the mitogen activated protein kinase (MAPK) pathway

2014 British Journal of Cancer

199. Efficacy of cryosurgery and 5-fluorouracil cream 0.5% combination therapy for the treatment of actinic keratosis. (Abstract)

Efficacy of cryosurgery and 5-fluorouracil cream 0.5% combination therapy for the treatment of actinic keratosis. Actinic keratoses (AKs) are on a continuum of progression to squamous cell carcinoma (SCC). The most common AK treatment modalities are lesion-directed cryosurgery and field-directed therapy with 5-fluorouracil (5-FU); however, side effects can affect patient compliance. This study was performed to determine the efficacy and perceived side effects of combination treatment

2014 Cutis Controlled trial quality: uncertain

200. Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + ALA Photodynamic Therapy

: Completed First Posted : September 15, 2014 Results First Posted : September 21, 2017 Last Update Posted : August 24, 2018 Sponsor: DUSA Pharmaceuticals, Inc. Information provided by (Responsible Party): DUSA Pharmaceuticals, Inc. Study Details Study Description Go to Brief Summary: The purpose of this study is to determine if Levulan photodynamic therapy (PDT) is safe and effective in the treatment of actinic keratoses (AK) on the face, following treatment with liquid nitrogen cryotherapy. Condition (...) Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + ALA Photodynamic Therapy Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + Aminolevulinic Acid (ALA) Photodynamic Therapy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached

2014 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>